A new study shows that the potential new coronary drug hydroxychloroquine that U.S. President Donald Trump has been touting does not actually prevent infection,media BGR reported. Patients who took hydroxychloroquine after exposure to COVID-19 were just as likely to be infected as those taking placebo drugs, the study said. Adding zinc doesn’t help either.
The drug is used to fight malaria and has a role to play in the treatment of lupus and rheumatoid arthritis. But some people think it can treat COVID-19. Earlier, after several White House officials tested positive for COVID-19, Mr. Trump surprised reporters by revealing that he was taking oxycodone. Since then, Mr. Trump has said he is willing to take hydroxychloroquine again.
Now, a new study of hydroxychloroquine suggests that hydroxychloroquine does not actually prevent neo-coronavirus infection, and when it comes to blocking the virus, it is just as effective as a placebo. Researchers from the University of Minnesota published their findings in the New England Journal of Medicine.
“We’re disappointed. We had hoped that the study would be successful,” study leader Dr. David Boulware told CBS News. “But our goal is to answer that question and conduct high-quality research. “
The study looked at 821 people in the U.S. and Canada who lived with people diagnosed with COVID-19, or were at high risk of developing COVID-19 for work-based reasons. These patients were randomly assigned to hydroxychloroquine or nutrient folic acid, which they began taking on the drug on the fourth day after exposure for 5 days. Patients don’t know what treatment they’re receiving, and the researchers don’t know.
After 14 days, 12 percent of patients who took hydroxychloroquine developed COVID-19, compared with 14 percent in the placebo group. “Basically it didn’t work. It doesn’t prevent infection,” Boulware said. “We’ll want to have a bigger effect” to justify the use of the drug. About 40 percent of people in the study had mild side effects, mainly stomach problems. The results were similar to those of zinc or vitamin C, and Trump’s treatment sedits included hydroxychloroquine, vitamin D and zinc, which he said was treated for two weeks.
The study did have some obvious limitations, including the fact that researchers recruited volunteers over the Internet, and they were unable to test them on COVID-19. These patients are mainly diagnosed by symptoms. In addition, doctors cannot monitor subjects or ensure that they take their medication as directed.
Dr. Myron Cohen of the University of North Carolina at Chapel Hill said the results were “more provocative than definitive.”
Boulware and his team have studied the role of hydroxychloroquine in COVID-19 treatment, and another study on the subject will soon be available.
A few days ago, a large observational study said the use of hydroxychloroquine in PATIENTs with COVID-19 was associated with a higher risk of death. The World Health Organization (WHO), France and the rest of Europe have therefore decided to stop hydroxychloroquine testing. Since then, other researchers have expressed concern about the results and the data that prompted them. After reviewing the safety information, WHO decided to proceed with the trial.